# A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

> **NCT07069309** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BioNTech SE** · enrollment: 760 (estimated)

## Conditions studied

- COVID-19
- SARS-COV-2 Infection

## Interventions

- **BIOLOGICAL:** BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

## Key facts

- **NCT ID:** NCT07069309
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2026-05-05
- **Final completion:** 2026-05-05
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07069309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07069309, "A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07069309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*